B 8 F
Biofrontera
Stock
Stock
ISIN: DE000A4BGGM7
Ticker: B8FK
DE000A4BGGM7
B8FK
Price
Price
CHART BY
Frequently asked questions
What is Biofrontera's market capitalization?
The market capitalization of Biofrontera is $16.24M. Market capitalization is a measure of the total market value of a publicly traded company. It is calculated by multiplying the current stock price by the total number of outstanding shares.
What is the Earnings Per Share (EPS) for Biofrontera?
Biofrontera's Earnings Per Share (EPS) over the trailing twelve months (TTM) is -$0.923. EPS indicates the company's profitability on a per-share basis.
What are the analyst ratings and target price for Biofrontera's stock?
Currently, 1 analysts cover Biofrontera's stock, with a consensus target price of $40.02. Analyst ratings provide insights into the stock's expected performance.
What is Biofrontera's revenue over the trailing twelve months?
Over the trailing twelve months, Biofrontera reported a revenue of $25.39M.
What is the EBITDA for Biofrontera?
Biofrontera's Earnings before interest, taxes, depreciation, and amortization (EBITDA) over the trailing twelve months is -$5.98M. EBITDA measures the company's overall financial performance.
How many employees does Biofrontera have, and what sector and industry does it belong to?
Biofrontera employs approximately 88 people. It operates in the Health Care sector, specifically within the Major Pharmaceuticals industry.
What is the free float of Biofrontera's shares?
The free float of Biofrontera is 5.56M. Free float refers to the number of shares available for public trading, excluding restricted shares.
Financials
- Market Cap
- $16.24M
- EPS (TTM)
- -$0.923
- Free Float
- 5.56M
- Revenue (TTM)
- $25.39M
- EBITDA (TTM)
- -$5.98M
Pricing
- 1D span
- $2.542$2.683
- 52W span
- $2.151$3.613
Analyst Ratings
The price target is $40.02 and the stock is covered by 1 analysts.
Buy
1
Hold
0
Sell
0
Information
Biofrontera AG engages in the research, development, and marketing of dermatological products. Its products include Ameluz, BF-RhodolesXepi and Belixos. The company was founded by Hermann Lübbert in 1997 and is headquartered in Leverkusen, Germany.
- Employees
- 88
- Industries
- Major Pharmaceuticals
- Sector
- Health Care
Identifier
- ISIN
- DE000A4BGGM7
- Primary Ticker
- B8FK
Knockouts
Real-time data from LSX · Fundamentals & EOD data from FactSet